热卖商品
新闻详情
BT2 | BCKDC Kinase 抑制剂 | MCE
来自 : www.medchemexpress.cn/bt...htm
发布时间:2021-03-24
BT2 (20 mg/kg/day; intraperitoneal injection; daily; for 7 days; C57BL/6J male mice) treatment robustly enhances BCKDC activity in the heart (12.3-fold) compared with the vehicle-treated animals. Less activation is obtained in muscle and kidney at 3.6- and 3.8-fold, respectively. The -fold activation of BCKDC activity in the above tissues correlates with decreased phosphorylation in heart, muscle, and kidney after the long term BT2 treatment. BT2 treatment reduces the protein levels of BDK in kidneys and heart[1].
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
BT2 Chemical Structure CAS No. : 34576-94-8 SizePriceStockQuantity 10 mM * 1 mL in DMSO ¥951 In-stock 1 mg ¥350 In-stock 5 mg ¥990 ...BT2 | BT 2 | BT-2 | Bcl-2 Family | Inhibitor | inhibitor | inhibitBT2 是 BCKDC 激酶 (BDK) 抑制剂,IC50 值为 3.19 μM。BT2 与 BDK 的结合会触发支链 α-酮酸脱氢酶复合物 (BCKDC) 的 N 末端结构域的螺旋运动,从而导致 BDK 与 BCKDC 分离。BT2 (compound 4) 也是一种有效的选择性的 Mcl-1 抑制剂,Ki 值为 59 μM。- 高纯度,全球文献引用。BT2
本文链接: http://btchemical.immuno-online.com/view-698748.html
发布于 : 2021-03-24
阅读(0)
最新动态
2021-03-24
2021-03-24
2021-03-24
2021-03-24
2021-03-24
2021-03-24
2021-03-24
2021-03-24
2021-03-24
2021-03-24
2021-03-24
2021-03-24
品牌分类
其他
联络我们